According to Royalty, a "sufficient number of these ADSs" voted against Elan's proposed $1 billion cash acquisition of a royalty stream from South San Francisco-based Theravance Inc

PDL Biopharma Inc., of Incline Village, Nev., filed a notice of arbitration against Genentech Inc. (part of Roche AG), of South San Francisco, with the American Arbitration Association in Voorhees, N.J., alleging, inter alia, that Genentech underpaid royalties going back to at least 2007 and impeded PDL's attempts to have Genentech's books and records inspected to determine whether Genentech's past payments to PDL were accurately calculated

Johnson & Johnson, of New Brunswick, N.J., said its Johnson & Johnson Innovation arm signed an agreement with the California Institute for Quantitative Biosciences (QB3) to allocate 5,000 square feet of the space in QB3's new 24,000-square foot biosciences incubator in San Francisco

Tunitas Therapeutics Inc., of San Francisco, was awarded a Small Business Innovation Research Phase II grant from the National Institute of Allergy and Infectious Disease

Hyperion Therapeutics Inc., of South San Francisco, said it completed the acquisition of Buphenyl (sodium phenylbutyrate) tablets and powder, from Ucyclyd Pharma Inc., a subsidiary of Valeant Pharmaceuticals International Inc., of Laval, Quebec, Buphenyl is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders (UCD...Onyx Pharmaceuticals Inc., of South San Francisco, and the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive

Pfizer Inc., of New York, said its Centers for Therapeutic Innovation (CTI) has expanded into the development of small-molecule drug candidates through a partnership with the University of California, San Francisco (UCSF

The Royalty offer was contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plc

Medivation Inc., of San Francisco, said partner Astellas Pharma Inc., of Tokyo, submitted an application for marketing approval in Japan for enzalutamide in prostate cancer

The Royalty offer was contingent on Elan's shareholders voting down all of its M&A transactions, including its recent $1 billion cash deal to buy a 21 percent stake in South San Francisco-based Theravance Inc.'s future royalty stream from the respiratory franchise it shares with London-based GlaxoSmithKline plc

Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec Inc

Genmab A/S, of Copenhagen, Denmark, reported that South San Francisco-based Genentech Inc., a unit of the Roche Group, and Weston, Mass.-based Biogen Idec Inc

Scientists at Bayer HealthCare's U.S. Innovation Center in San Francisco will work collaboratively with counterparts at QB3 and Mission Bay Capital in the structured public-private partnership, with QB3 bringing up to 60 companies a year from its network for Bayer to evaluate for potential partnerships

Curis earned a $4 million milestone payment from Genentech Inc., of South San Francisco (a unit of Roche AG), as a result of the Australian approval

Jennerex Biotherapeutics Inc., of San Francisco, said the FDA granted orphan drug status for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of hepatocellular carcinoma (HCC

VistaGen Therapeutics Inc., of South San Francisco, said its human pluripotent stem cell-derived cardiomyocytes were used by collaboration partner Duke University to grow three-dimensional (3D) human heart muscle

Hyperion Therapeutics Inc., of South San Francisco, said the FDA notified the firm that Ravicti (glycerol phenylbutyrate) qualified for orphan drug exclusivity, giving the product exclusivity on the market for seven years from the date of approval on Feb. 1

Genentech Inc., of South San Francisco, a member of the Roche Group, said the FDA approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA

Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, said the European Committee for Medicinal Products for Human Use recommended approval of Xtandi (enzalutamide) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy...Theravance Inc., of South San Francisco, said its board approved plans to separate its businesses into two independently traded companies

Achaogen Inc., of South San Francisco, was awarded a $60 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) supporting a global Phase III superiority study that will evaluate the efficacy and safety of plazomicin in treating patients with serious Gram-negative bacterial infections due to Carbapenem-resistant Enterobacteriaceae